In the hidden platform test, the escape latency and total traveling distance in E2‐ or PPT‐treated OVX APP/PS1 (AD + E2 or AD + PPT) mice were significantly shorter than that in saline‐treated OVX APP/PS1 (AD) mice beginning on the third day (Figure 6a–c). The gene discussed is APP; the disease is Alzheimer disease.